Biogen and VTT launching collaboration: Alzheimer's Disease Challenge for start-ups aims at finding digital solutions

Slush 2021
Finland

-

Alzheimer’s Disease Challenge is looking for digital solutions for the prevention and early detection of Alzheimer’s disease, patient and care giver support, and healthcare system support in Alzheimer’s Disease management. Apply now to participate!

Memory disorders and, in particular, Alzheimer’s disease, are one of the greatest social challenges of our time. In 2018, there were 9.7 million people affected by Alzheimer’s disease or other forms of dementia in Europe alone.1 By 2030, the number of people with such illnesses is estimated to be 14 million, causing not only human suffering but also a cost of EUR 250 billion to society.2 

Biogen and VTT challenge start-ups working on digital health care solutions to participate in a joint workshop as part of the world’s leading start-up event, Slush, on 1 December 2021. Start-ups selected for the Alzheimer’s Disease Challenge will have the opportunity to spar over the implementation and deployment of a digital solution on the treatment path of a patient suffering from Alzheimer’s disease, together with clinical experts, investors and specialists from VTT and Biogen.

Further information on the Alzheimer’s Disease Challenge and application instructions can be found here. Start-ups may apply until 31 October 2021. Start-ups selected for the challenge will receive a notification of the decision and a ticket to Slush 2021 no later than 15 November 2021. 

About Biogen
Biogen’s mission is to be a pioneer in neurosciences. Biogen studies, develops and delivers innovative treatments worldwide to people with severe neurological and neurodegenerative diseases or associated diseases. Biogen is one of the first biotechnology companies in the world.

About VTT
VTT is a visionary research, development and innovation partner. We tackle global challenges and turn them into opportunities for sustainable growth. We go beyond the obvious to help society and companies grow through technological innovations.

 

Further information:

Biogen

Andrei Nahkala, Head of Corporate Affair, Biogen Finland Oy
+358405932127, Andrei.nahkala@biogen.com

 

VTT

Emmi Reijula, Senior Scientist, VTT Technical Research Centre of Finland 
+358504340077, emmi.reijula@vtt.fi

 

Sources:

1)    Alzheimer Europe, dementia in Europe Yearbook 2019, Estimating the prevalence of dementia in Europe
2)    EFPIA, https://efpia.eu/about-medicines/use-of-medicines/disease-specific-groups/wewontrest-until-alzheimer-s-patients-have-a-brighter-future/, retrieved on 28 September 2021
 

Share
Emmi Reijula

Emmi Reijula

Senior Scientist
Industries